临床试验/jRCT2011230029

jRCT2011230029已完成不适用

33-104 : Drug Use-Results Survey of OPDIVO (Unresectable advanced/recurrent malignant pleural mesothelioma that has progressed after cancer chemotherapy)

Ono Pharmaceutical Co.,LTD0 个研究点目标入组 100 人开始时间: 2018年12月18日最近更新: 2024年9月4日

试验速览

阶段: 不适用
状态: 已完成
发起方: Ono Pharmaceutical Co.,LTD
入组人数: 100
主要终点: Occurrence status of adverse drug reactions and infections

研究概览研究设计入排标准结局指标研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Observational

入排标准

年龄范围: No limit 至 No limit（—）
性别: All

入选标准

•Patients with unresectable advanced/recurrent malignant pleural mesothelioma that has progressed after cancer chemotherapy, who have recieved OPDIVO for the first time

排除标准

•Patients who have received OPDIVO previously

结局指标

主要结局

Occurrence status of adverse drug reactions and infections

Occurrence status of adverse drug reactions and infections

Factors that are considered to affect safety

Factors that are considered to affect safety

Adverse events

Adverse events

次要结局

未报告次要终点

研究者

发起方

Ono Pharmaceutical Co.,LTD

相似试验

进行中（未招募）

33-105 : Drug Use-Results Survey of OPDIVO

jRCT2041240121Ono Pharmaceutical Co.,LTD100

33-104 : Drug Use-Results Survey of OPDIVOnresectable advanced/recurrent malignant pleural mesothelioma that has progressed after cancer chem

JPRN-jRCT2011230029Kuro Toshihiko100

Drug Use-Results Survey of OPDIVO (malignant melanoma)Malignant melanoma

JPRN-jRCT1080223217ONO PHARMACEUTICAL CO., LTD.1,700

Drug Use-Results Survey of OPDIVO (head and neck cancer)Head and Neck Cancer

JPRN-jRCT1080224012ONO PHARMACEUTICAL CO.,LTD.400

33-506 :Special Drug Use-Results Survey of OPDIVO

jRCT2041240115Ono Pharmaceutical Co.,LTD30

33-104 : Drug Use-Results Survey of OPDIVO | 临床试验